These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30807820)

  • 1. Inhibiting mGluR5 activity by AFQ056/Mavoglurant rescues circuit-specific functional connectivity in Fmr1 knockout mice.
    Zerbi V; Markicevic M; Gasparini F; Schroeter A; Rudin M; Wenderoth N
    Neuroimage; 2019 May; 191():392-402. PubMed ID: 30807820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice.
    Gantois I; Pop AS; de Esch CE; Buijsen RA; Pooters T; Gomez-Mancilla B; Gasparini F; Oostra BA; D'Hooge R; Willemsen R
    Behav Brain Res; 2013 Feb; 239():72-9. PubMed ID: 23142366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant.
    Pop AS; Levenga J; de Esch CE; Buijsen RA; Nieuwenhuizen IM; Li T; Isaacs A; Gasparini F; Oostra BA; Willemsen R
    Psychopharmacology (Berl); 2014 Mar; 231(6):1227-35. PubMed ID: 23254376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragile X mice have robust mGluR5-dependent alterations of social behaviour in the Automated Tube Test.
    de Esch CE; van den Berg WE; Buijsen RA; Jaafar IA; Nieuwenhuizen-Bakker IM; Gasparini F; Kushner SA; Willemsen R
    Neurobiol Dis; 2015 Mar; 75():31-9. PubMed ID: 25562659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile X mice.
    Michalon A; Bruns A; Risterucci C; Honer M; Ballard TM; Ozmen L; Jaeschke G; Wettstein JG; von Kienlin M; Künnecke B; Lindemann L
    Biol Psychiatry; 2014 Feb; 75(3):189-97. PubMed ID: 23910948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rescue of Fmr1
    Westmark PR; Dekundy A; Gravius A; Danysz W; Westmark CJ
    Neurobiol Dis; 2018 Nov; 119():190-198. PubMed ID: 30125640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization.
    Vranesic I; Ofner S; Flor PJ; Bilbe G; Bouhelal R; Enz A; Desrayaud S; McAllister K; Kuhn R; Gasparini F
    Bioorg Med Chem; 2014 Nov; 22(21):5790-803. PubMed ID: 25316499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome.
    Hessl D; Harvey D; Sansone S; Crestodina C; Chin J; Joshi R; Hagerman RJ; Berry-Kravis E
    PLoS One; 2019; 14(1):e0209984. PubMed ID: 30653533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.
    Yan QJ; Rammal M; Tranfaglia M; Bauchwitz RP
    Neuropharmacology; 2005 Dec; 49(7):1053-66. PubMed ID: 16054174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome.
    Thomas AM; Bui N; Graham D; Perkins JR; Yuva-Paylor LA; Paylor R
    Behav Brain Res; 2011 Oct; 223(2):310-21. PubMed ID: 21571007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome.
    Thomas AM; Bui N; Perkins JR; Yuva-Paylor LA; Paylor R
    Psychopharmacology (Berl); 2012 Jan; 219(1):47-58. PubMed ID: 21656124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.
    Berry-Kravis E; Des Portes V; Hagerman R; Jacquemont S; Charles P; Visootsak J; Brinkman M; Rerat K; Koumaras B; Zhu L; Barth GM; Jaecklin T; Apostol G; von Raison F
    Sci Transl Med; 2016 Jan; 8(321):321ra5. PubMed ID: 26764156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.
    Jacquemont S; Curie A; des Portes V; Torrioli MG; Berry-Kravis E; Hagerman RJ; Ramos FJ; Cornish K; He Y; Paulding C; Neri G; Chen F; Hadjikhani N; Martinet D; Meyer J; Beckmann JS; Delange K; Brun A; Bussy G; Gasparini F; Hilse T; Floesser A; Branson J; Bilbe G; Johns D; Gomez-Mancilla B
    Sci Transl Med; 2011 Jan; 3(64):64ra1. PubMed ID: 21209411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of mavoglurant and its potential for the treatment of fragile X syndrome.
    Gomez-Mancilla B; Berry-Kravis E; Hagerman R; von Raison F; Apostol G; Ufer M; Gasparini F; Jacquemont S
    Expert Opin Investig Drugs; 2014 Jan; 23(1):125-34. PubMed ID: 24251408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of GluN2A NMDA receptors ameliorates synaptic plasticity deficits in the Fmr1
    Lundbye CJ; Toft AKH; Banke TG
    J Physiol; 2018 Oct; 596(20):5017-5031. PubMed ID: 30132892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered neocortical rhythmic activity states in Fmr1 KO mice are due to enhanced mGluR5 signaling and involve changes in excitatory circuitry.
    Hays SA; Huber KM; Gibson JR
    J Neurosci; 2011 Oct; 31(40):14223-34. PubMed ID: 21976507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.
    Scharf SH; Jaeschke G; Wettstein JG; Lindemann L
    Curr Opin Pharmacol; 2015 Feb; 20():124-34. PubMed ID: 25488569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in sensitivity of reward and motor behavior to dopaminergic, glutamatergic, and cholinergic drugs in a mouse model of fragile X syndrome.
    Fish EW; Krouse MC; Stringfield SJ; Diberto JF; Robinson JE; Malanga CJ
    PLoS One; 2013; 8(10):e77896. PubMed ID: 24205018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro.
    Tabolacci E; Pirozzi F; Gomez-Mancilla B; Gasparini F; Neri G
    BMC Med Genet; 2012 Mar; 13():13. PubMed ID: 22397687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice.
    Han K; Chen H; Gennarino VA; Richman R; Lu HC; Zoghbi HY
    Hum Mol Genet; 2015 Apr; 24(7):1813-23. PubMed ID: 25432536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.